Corporate Presentations

Date Headline
19-Oct-20
19-Oct-20
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
15-Oct-20
15-Oct-20
Actinogen Presentation and Planned Conference Call
08-Sep-20
08-Sep-20
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) pre-recorded presentation with Dr Bill Ketelbey
08-Sep-20
08-Sep-20
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) investor presentation
31-Jul-20
31-Jul-20
FNN CEO Showcase: Actinogen Medical (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
15-Jun-20
15-Jun-20
Bio Digital 2020: Company presentation and audio. Dr Bill Ketelbey provides company update “Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease”
08-Jun-20
08-Jun-20
Bio Digital 2020: Company presentation “Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease”
08-Jun-20
08-Jun-20
BIO Digital 2020: Company presentation for partnering meetings
29-Apr-20
29-Apr-20
AAT/AD-PD 2020: Actinogen Full Presentation with Audio presented by Professor Craig Ritchie, Chair of Actinogen’s Xanamem Clinical Advisory Board. Chronically elevated cortisol and cognitive impairment: The therapeutic potential of Xanamem, a potent inhibitor of the 11β-HSD1 enzyme
29-Apr-20
29-Apr-20
AAT-AD/PD 2020: Actinogen’s Presentation Summary
29-Apr-20
29-Apr-20
AAT-AD/PD 2020: Actinogen Presentation Only Excluding Audio
29-Jan-20
29-Jan-20
3rd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey, CEO Actinogen Medical Ltd presentation in San Francisco, USA
25-Nov-19
25-Nov-19
AGM 2019: Managing Directors Address to Shareholders
25-Nov-19
25-Nov-19
AGM 2019: Managing Director’s Presentation
08-Nov-19
08-Nov-19
90 Seconds with… Actinogen Medical. Dr Bill Ketelbey tells us about his AusBiotech Invest presentation and upcoming newsflow
06-Nov-19
06-Nov-19
Australian Microcap Investment Conference 2019: Actinogen Medical presentation
25-Sep-19
25-Sep-19
AAIC Satellite Symposium: Poster Presentation. Chronically Elevated Cortisol and Cognitive Impairment: The Therapeutic Potential of Xanamem™, a Potent Inhibitor of the 11β-HSD1 Enzyme
26-Jun-19
26-Jun-19
Investor Presentation Jun 2019: A novel approach to treating cognitive impairment and Alzheimer’s disease
06-Jan-19
06-Jan-19
Investor Presentation Jan 2019: Presentation at Sachs Neuroscience Innovation Forum during JPM Week
06-Jan-19
06-Jan-19
2nd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey presentation in San Francisco, USA
28-Nov-18
28-Nov-18
AGM: Managing Director’s Presentation 2018
28-Nov-18
28-Nov-18
Actinogen Medical XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.
26-Nov-18
26-Nov-18
Investor Presentation Nov 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
30-Oct-18
30-Oct-18
Australia Biotech Invest & Partnering 2018: Oct 2018
17-Oct-18
17-Oct-18
Australian Microcap Investment Conference Oct 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
25-Sep-18
25-Sep-18
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
12-Sep-18
12-Sep-18
Singapore Healthcare Investor Day Sep 2018: Alzheimer’s Treatment Needs a New Approach – Xanamem
04-Jun-18
04-Jun-18
BIO International Convention Jun 2018: Presentation ‘Alzheimer’s Treatment Needs a New Approach – Xanamem’
30-May-18
30-May-18
Investor Conference Call Audio: 30 May 2018
28-May-18
28-May-18
Investor Presentation: May/Jun 2018
05-Apr-18
05-Apr-18
Investor Open Briefing March 2018: Dr Bill Ketelbey, CEO, and Dr Geoff Brooke, Chairman, presented at the Investor Briefing in Sydney providing an update on Actinogen Medical and the exciting developments with Xanamem in Alzheimer’s disease
19-Mar-18
19-Mar-18
Presentation: Investor Open Briefing: Mar 2018: Alzheimer Treatment Needs a New Approach – Xanamem
29-Nov-17
29-Nov-17
AGM: Managing Director’s Presentation 2017
29-Nov-17
29-Nov-17
Actinogen Medical & KaRa Minds: Leading Alzheimer’s Researchers Address to Shareholders
Dr Bill Ketelbey speaks with Prof Ralph Martins and Associate Prof Kathryn Goozee from KaRa Minds following the Actinogen Medical AGM
24-Oct-17
24-Oct-17
Australian Microcap Investment Conference: Interview with Dr Bill Ketelbey
16-Oct-17
16-Oct-17
Investor Presentation: Oct 2017
16-Oct-17
16-Oct-17
Australia Biotech Invest Presentation: Oct 2017
16-Oct-17
16-Oct-17
Alzheimer’s Australia 17th Biennial National Dementia Conference Poster Presentation: Oct 2017
16-Oct-17
16-Oct-17
Australian Microcap Investment Conference Presentation: Oct 2017
27-Mar-17
27-Mar-17
Investor Presentation: March 2017
12-Dec-16
12-Dec-16
Xanamem Research Presentation by Prof Craig Ritchie at CTAD San Diego
30-Nov-16
30-Nov-16
AGM Presentation 2016
26-Sep-16
26-Sep-16
Understanding Alzheimer’s Conference at Novotel Melbourne
21-Sep-16
21-Sep-16
Understanding Alzheimer’s Symposium: Dr Bill Ketelbey Presentation
21-Sep-16
21-Sep-16
Understanding Alzheimer’s Symposium: Program
10-Mar-16
10-Mar-16
Investor Presentation: Developing Xanamem for Alzheimer’s disease – Cortisol Hypothesis: March 2016
12-Nov-15
12-Nov-15
AGM Presentation 2015
14-Apr-15
14-Apr-15
Xanamem™ Clinical Advisory Board Conference Call Transcript
14-Apr-15
14-Apr-15
Xanamem™ Clinical Advisory Board Conference Call Recording
13-Apr-15
13-Apr-15
Investor Presentation: Developing Xanamem™ for Alzheimer’s Dementia: April 2015
09-Mar-15
09-Mar-15
Investor Presentation: Developing Xanamem™ for Alzheimer’s Dementia: March 2015
09-Jan-15
09-Jan-15
JP Morgan Annual Healthcare Conference: Developing Xanamem™ for Alzheimer’s Dementia: January 2015